AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
종목 코드 AIM
회사 이름AIM ImmunoTech Inc
상장일Jul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
직원 수21
유형Ordinary Share
회계 연도 종료Jul 12
주소2117 Sw Highway 484
도시OCALA
증권 거래소The Toronto Stock Exchange
국가United States of America
우편 번호32801
전화13524487797
웹사이트https://aimimmuno.com/
종목 코드 AIM
상장일Jul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음